1 completed, 1 suspended. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 1, Suspended 1 |
| Phase 2 | 1 | Suspended 1 |
Follow KB004: new trials by email Literature Review of KB004 trials Research Report on KB004
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Trial of KB004 in Patients With Glioblastoma KB004 - Glioblastoma | Phase 1 | Completed | Olivia Newton-John Cancer Research Institute | 12 | 2017-12-05 | 2021-11-04 |
| Study of KB004 in Subjects With Hematologic Malignancies (Myelodysplastic Syndrome, MDS, Myelofibrosis, MF) KB004, Monoclonal Antibody - Myelodysplastic Syndrome (MDS), Myelofibrosis (MF) | Phase 1 / Phase 2 | Suspended | Humanigen, Inc. | 120 | 2010-09-01 | 2015-11-17 |
Glioblastoma (1) · Leukemia (1) · Myelodysplastic Syndromes (1) · Myeloproliferative Disorders (1) · Neoplasms (1) · Primary Myelofibrosis (1)
Humanigen, Inc. (1) · Olivia Newton-John Cancer Research Institute (1)
Australia (2) · United States (1)
Hui Gan (1) · Morgan Lam (1)